This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mack, M. J. Search for Related Content PubMed PubMed Citation Articles by Mack, M. J. Related Collections CV surgery: valvular disease Related Article

(Circulation. 2006;113:2269-2271.)
© 2006 American Heart Association, Inc.

Editorial

Percutaneous Mitral Valve Repair

A Fertile Field of Innovative Treatment Strategies

Michael J. Mack, MD

From Medical City Dallas Hospital, and Cardiopulmonary Research Science and Technology Institute (CRSTI), Dallas, Tex.

Correspondence to Michael J. Mack, MD, 7777 Forest Ln, Suite A-323, Dallas, TX 75230. E-mail mjmack@earthlink.net

Key Words: Editorials • mitral valve • regurgitation • valves

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The mitral valve is a complex structure composed of the leaflets, annulus, chordae tendineae, and papillary muscles. Competency of the mitral valve is dependent on the proper function of each of these component structures. The pathophysiological triad of mitral regurgitation (MR) was originally described by Carpentier in 1983.¹ It included the etiology of the valve lesion, the valve lesion itself, and the resultant valve dysfunction. He subsequently described a classification of leaflet dysfunction in MR that is commonly used and relevant for patient selection and evaluation of percutaneous mitral valve repair (PMVR). In type I dysfunction, there is normal leaflet motion, and valvular incompetence is due to either annular dilatation or leaflet perforation. Type II mitral dysfunction includes patients with increased leaflet motion (prolapse) of one or both leaflets so that there is failure of coaptation during systole resulting in mitral regurgitation. Patients in this category are those with degenerative myxomatous disease of the valve with chordal and/or papillary muscle elongation or rupture. Patients with type IIIa dysfunction have restriction of leaflet motion during both systole and diastole caused by leaflet and subvalvular apparatus thickening and fusion (rheumatic heart disease). The cause of valvular incompetence in patients with type IIIb dysfunction is restricted leaflet motion during systole caused by apical displacement of the papillary muscle from ventricular enlargement in dilated cardiomyopathy (functional MR) and lateral displacement of a posterior papillary muscle in ischemic MR. Patients may have a combination of causes of dysfunction (annular dilation, apical papillary muscle displacement), especially . . . [Full Text of this Article]

Related Article:

Percutaneous Septal Sinus Shortening: A Novel Procedure for the Treatment of Functional Mitral Regurgitation

Jason H. Rogers, John A. Macoviak, David A. Rahdert, Patricia A. Takeda, Igor F. Palacios, and Reginald I. Low
Circulation 2006 113: 2329-2334. [Abstract] [Full Text]

This article has been cited by other articles:

				P. A. Grayburn Should we operate on asymptomatic patients with severe mitral regurgitation? J. Am. Coll. Cardiol. Img., March 1, 2008; 1(2): 142 - 144. [Full Text] [PDF]

				E. Lansac, I. Di Centa, N. Al Attar, D. Messika-Zeitoun, R. Raffoul, A. Vahanian, and P. Nataf Percutaneous mitral annuloplasty through the coronary sinus: an anatomic point of view. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 376 - 381. [Abstract] [Full Text] [PDF]

				M. J. Mack Coronary Sinus in the Management of Functional Mitral Regurgitation: The Mother Lode or Fool's Gold? Circulation, August 1, 2006; 114(5): 363 - 364. [Full Text] [PDF]